Washington University School of Medicine in St. Louis (WashU Medicine) has been awarded a significant five-year, $10.8 million grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH). This funding renewal aims to advance the institution's ongoing research in
Researchers at the Perelman School of Medicine at the University of Pennsylvania have made a significant breakthrough in personalized medicine and cancer treatment. By using patient-derived glioblastoma (GBM) organoids, they have developed a method to model patient responses to CAR-T cell therapy
Recent research from Weill Cornell Medicine has unveiled a promising preclinical discovery that could significantly enhance the effectiveness of cancer immunotherapy for B-cell non-Hodgkin lymphomas (B-NHL). The study focuses on the use of EZ## inhibitors, an emerging class of anticancer drugs, in
In a remarkable breakthrough in breast cancer treatment, a novel cell-based immunotherapy developed by Dr. Gary Koski from Kent State University and Dr. Brian J. Czerniecki from the Moffitt Cancer Center has been recently accepted for publication in JAMA Oncology. This innovative approach harnesses
For lymphoma patients, particularly those facing relapsed or refractory large B cell lymphoma (LBCL), CAR T cell therapy represents a beacon of hope. This promising treatment, epitomized by Breyanzi (lisocabtagene maraleucel), offers a new avenue for those who have exhausted conventional treatment
Synthetic biology represents a revolutionary discipline that applies engineering principles to biology, aiming to develop cells into sophisticated micro-factories capable of producing essential materials. With the potential to spearhead advancements across numerous industries—including medicine, a
